Skip to content
Screener

Ionis Pharmaceuticals IONS Operating Lease Liabilities

Operating Lease Liabilities at other companies

Arrowhead Research logo
Arrowhead ResearchARWR
$100.11M-6.9%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$10.6M+24.9%
ALN
Alnylam PharmaceuticalsALNY
$210.5M-6.2%
Wave Life Sciences logo
Wave Life SciencesWVE
$40.08M+195%
Intellia Therapeutics logo
Intellia TherapeuticsNTLA
$50.07M-33.8%
CalAmp logo
CalAmpCAMP
$1.74M-63.0%

Other financials

Income statement

See full
Revenue$267.9M-40.7%
Gross profit$265.2M-40.8%
Operating income-$102.3M-173%
Net income-$114.6M-193%
EPS (diluted)-$0.69-199%

Balance sheet

See full
Cash & equivalents$350.1M+17.7%
Total debt$262.5M-67.0%
Total equity$439.7M-30.4%
Total assets$3.0B+0.3%

Cash flow

See full
Operating cash flow-$792.8M-426%
CapEx$16.1M+30.7%
Free cash flow-$814.6M-399%

Valuation

See full
Market cap$9.06B+39.6%
Enterprise value$8.97B+28.4%
P/S10.4×+3.5×

Profitability

See full
Gross margin98.2%-0.7pp
Operating margin-68%-234pp
Net margin-64.7%-299pp
FCF margin-77.4%+35.3pp

Returns & leverage

See full
Return on equity-105.5%+336pp
Debt / equity0.6×-0.7×
Current ratio7.9×+5.0×

Where this comes from

Reported directly by Ionis Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.

The source filing: Ionis Pharmaceuticals’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 5:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000874015-26-000251
Line itemJune 30, 2026December 31, 2025
0 percent convertible senior notes due 2030, net753,356751,495
1.75 percent convertible senior notes due 2028, net569,255567,830
Liability related to sale of future royalties, net562,574551,353
Long-term lease liabilities262,476262,383
Long-term obligations28,43528,118
Total liabilities2,554,7643,034,747
Stockholders’ equity:
Common stock, $0.001 par value; 300,000,000 shares authorized, 165,636,792 and 163,304,875 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively166163

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Ionis Pharmaceuticals's operating lease liabilities?
Ionis Pharmaceuticals (IONS) reported operating lease liabilities of $262.48M in Q2 2026.
How has Ionis Pharmaceuticals's operating lease liabilities changed year-over-year?
Ionis Pharmaceuticals's operating lease liabilities increased by 59.7% year-over-year, from $164.38M to $262.48M.
What is the long-term trend for Ionis Pharmaceuticals's operating lease liabilities?
Over 4 years (2021 to 2025), Ionis Pharmaceuticals's operating lease liabilities has grown at a 91.7% compound annual growth rate (CAGR), from $19.43M to $262.38M.
What does operating lease liabilities mean?
Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.

Ask your AI about Ionis Pharmaceuticals's operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude